Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - JMP Securities raised its price target on OptimizeRX (NASDAQ:OPRX) to $20.00 from $14.00 on Monday, while maintaining a Market Outperform rating following the company’s strong second-quarter results. According to InvestingPro data, the stock has surged over 255% year-to-date, with analysts setting targets ranging from $11 to $27.
OptimizeRX reported second-quarter revenue of $29.2 million, representing a 55% year-over-year increase. This performance significantly exceeded both JMP’s estimate of $22.2 million and the consensus expectation of $22.3 million.
The healthcare technology company also posted EBITDA of $5.8 million for the quarter, surpassing JMP’s estimate and consensus forecasts of $1.3 million. The company’s EBITDA margin reached 19.7% in the second quarter, compared to 2.5% in the same period last year.
JMP analyst Constantine Davides reiterated the firm’s Market Outperform rating on OptimizeRX shares in light of these results, expressing confidence in the company’s performance.
The price target increase represents a significant upward revision, with the new $20 target reflecting JMP’s positive outlook following OptimizeRX’s quarterly earnings beat.
In other recent news, OptimizeRx Corp reported strong financial results for the second quarter of 2025, significantly outperforming analyst expectations. The company achieved earnings per share of $0.24, a substantial increase compared to the anticipated $0.02, resulting in an impressive 1100% earnings surprise. Additionally, OptimizeRx’s revenue reached $29.2 million, surpassing the projected $22.26 million by 31.18%. These results reflect a robust performance and have garnered attention from investors. Analyst firms have taken note of these developments, although specific upgrades or downgrades were not mentioned in the recent analysis. These figures highlight the company’s ability to exceed market expectations. The notable earnings and revenue achievements are key points of interest for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.